Zydus Partners with Myriad Genetics to Bring Advanced Cancer Risk Assessment Tests to India
核心洞察
Zydus Lifesciences has signed an exclusive agreement with US-based Myriad Genetics to launch precision cancer diagnostic tests in India, including MyRisk Hereditary Cancer Test, MyChoice HRD Plus, and Prolaris Prostate Cancer Prognostic Test.
The MyRisk Test evaluates 63 genes associated with hereditary cancer risk and provides personalized five-year and lifetime breast cancer risk assessments when combined with clinical factors.
These genomic decision-support tools, already widely adopted in North America and Europe, will empower Indian oncologists to develop personalized treatment plans and identify hereditary cancer risks in patients and families.
Ahmedabad-based Zydus Lifesciences Ltd has entered into an exclusive agreement with US molecular diagnostics leader Myriad Genetics (搜索) to introduce advanced cancer risk assessment and prognostic tests to the Indian healthcare market. The partnership will bring three key diagnostic platforms to Indian patients, clinicians, and healthcare systems: MyRisk Hereditary Cancer Test, MyChoice HRD Plus Test, and Prolaris Prostate Cancer Prognostic Test.
Comprehensive Genetic Testing Portfolio
The MyRisk Hereditary Cancer Test represents the most comprehensive offering in the partnership, analyzing 63 clinically significant genes associated with hereditary cancer risk, including BRCA1 (搜索), BRCA2 (搜索), PALB2 (搜索), ATM (搜索), TP53 (搜索), MLH1 (搜索), and MSH2 (搜索). The test covers more than 11 different cancer types, including breast, ovarian, lung, pancreatic, colorectal, endometrial, prostate, gastric, and melanoma cancers.
When combined with family history and clinical factors such as breast density, the MyRisk Test with RiskScore provides eligible patients with individualized five-year and remaining lifetime breast cancer risk assessments. This comprehensive approach enables personalized prevention strategies and screening plans tailored to individual genetic profiles.
The test is particularly relevant for patients with cancer history in breast, ovarian, colorectal, endometrial, pancreatic, prostate, or melanoma cancers, individuals with strong family history of related or early-onset cancers, those with known familial mutations like BRCA1 (搜索)/2, PALB2 (搜索), CHEK2, ATM (搜索), or Lynch genes, and proactive individuals considering risk-reducing surgery or long-term risk assessment.
Targeted Cancer Treatment Support
The MyChoice HRD Plus Test addresses the growing need for precision oncology in ovarian cancer treatment. This comprehensive tumor test determines Homologous Recombination Deficiency (HRD) status by assessing genomic alterations in genes such as BRCA1 (搜索) and BRCA2 (搜索), combined with Genomic Instability Score (GIS) status using Myriad's proprietary algorithm. The test enables healthcare professionals to identify patients with advanced ovarian cancer who are more likely to respond to targeted therapies.
For prostate cancer management, the Prolaris Test offers an RNA-based gene expression analysis that quantifies tumor aggressiveness and provides patient-specific risk scores. The test assists clinicians in determining whether active surveillance is appropriate, assessing the need for immediate treatment, and evaluating 10-year risk of metastasis and prostate cancer-specific mortality.
Addressing India's Cancer Burden
"This agreement marks a major step in expanding access to precision diagnostic tests for cancer treatment in India," said Dr. Sharvil P. Patel, Managing Director of Zydus. "The prostate and ovarian cancer tests help doctors with actionable insights to develop personalised treatment plans, predict disease progression, arrive at treatment decisions and streamline clinical workflows. We are also bringing a test which will help identify hereditary risks in patients and their families."
Brian Donnelly, Chief Commercial Officer for Myriad Genetics (搜索), emphasized the collaboration's significance: "This collaboration with Zydus is an important step forward in expanding precision oncology across India. Myriad tests aim to empower clinicians with actionable information to assess risk, understand tumour biology, and guide truly personalised care with greater clarity, confidence, and hope as they navigate critical health decisions."
Global Validation and Local Implementation
These diagnostic platforms have been widely adopted across North America, Europe, and major global cancer centers, providing a foundation of clinical validation for their introduction to the Indian market. Under the exclusive agreement, Zydus will be responsible for marketing, creating awareness, accessing, and engaging clinicians across India to ensure proper implementation and utilization of these genomic decision-support tools.
The partnership addresses the increasing incidence of cancers globally and specifically in India, where prostate cancer incidence is rising. The introduction of these clinically validated tools for personalized therapy decisions represents a significant advancement in precision oncology capabilities for Indian healthcare providers, potentially improving clinical outcomes and supporting patients in their fight against cancer.